| Id |
Subject |
Object |
Predicate |
Lexical cue |
| 14743461-0#19#35#diseaseC0376358 |
364-591 |
diseaseC0376358 |
denotes |
psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s |
| 14743461-0#52#55#gene354 |
723-726 |
gene354 |
denotes |
PSA |
| 14743461-0#52#55#gene9520 |
723-726 |
gene9520 |
denotes |
PSA |
| 14743461-0#52#55#gene5324 |
723-726 |
gene5324 |
denotes |
PSA |
| 14743461-0#52#55#gene5627 |
723-726 |
gene5627 |
denotes |
PSA |
| 14743461-0#52#55#gene29968 |
723-726 |
gene29968 |
denotes |
PSA |
| 14743461-7#155#170#diseaseC0600139 |
1149-1164 |
diseaseC0600139 |
denotes |
prostate cancer |
| 14743461-7#230#233#gene354 |
1224-1227 |
gene354 |
denotes |
PSA |
| 14743461-7#230#233#gene9520 |
1224-1227 |
gene9520 |
denotes |
PSA |
| 14743461-7#230#233#gene5324 |
1224-1227 |
gene5324 |
denotes |
PSA |
| 14743461-7#230#233#gene5627 |
1224-1227 |
gene5627 |
denotes |
PSA |
| 14743461-7#230#233#gene29968 |
1224-1227 |
gene29968 |
denotes |
PSA |
| 230#233#gene29968155#170#diseaseC0600139 |
14743461-7#230#233#gene29968 |
14743461-7#155#170#diseaseC0600139 |
associated_with |
PSA,prostate cancer |
| 230#233#gene354155#170#diseaseC0600139 |
14743461-7#230#233#gene354 |
14743461-7#155#170#diseaseC0600139 |
associated_with |
PSA,prostate cancer |
| 230#233#gene5324155#170#diseaseC0600139 |
14743461-7#230#233#gene5324 |
14743461-7#155#170#diseaseC0600139 |
associated_with |
PSA,prostate cancer |
| 230#233#gene5627155#170#diseaseC0600139 |
14743461-7#230#233#gene5627 |
14743461-7#155#170#diseaseC0600139 |
associated_with |
PSA,prostate cancer |
| 230#233#gene9520155#170#diseaseC0600139 |
14743461-7#230#233#gene9520 |
14743461-7#155#170#diseaseC0600139 |
associated_with |
PSA,prostate cancer |
| 52#55#gene2996819#35#diseaseC0376358 |
14743461-0#52#55#gene29968 |
14743461-0#19#35#diseaseC0376358 |
associated_with |
PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s |
| 52#55#gene35419#35#diseaseC0376358 |
14743461-0#52#55#gene354 |
14743461-0#19#35#diseaseC0376358 |
associated_with |
PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s |
| 52#55#gene532419#35#diseaseC0376358 |
14743461-0#52#55#gene5324 |
14743461-0#19#35#diseaseC0376358 |
associated_with |
PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s |
| 52#55#gene562719#35#diseaseC0376358 |
14743461-0#52#55#gene5627 |
14743461-0#19#35#diseaseC0376358 |
associated_with |
PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s |
| 52#55#gene952019#35#diseaseC0376358 |
14743461-0#52#55#gene9520 |
14743461-0#19#35#diseaseC0376358 |
associated_with |
PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s |
